Ibudilast (AV-411)

Bibliography

• DWORKIN RH, BACKONJA M, ROWBOTHAM MC et al.: Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol. (2003) 60(11):1524-1534.
   PubMed Web of Science ®Google Scholar
• OSSIPOV MH, PORRECA F: Challenges in the development of novel treatment strategies for neuropathic pain. NeuroRx (2005) 2(4):650-661.
   PubMedGoogle Scholar
• MILLAN MJ: The induction of pain: an integrative review. Prog. Neurobiol. (1999) 57(1):1-164.
   PubMed Web of Science ®Google Scholar
• WOOLF CJ, SALTER MW: Neuronal plasticity: increasing the gain in pain. Science (2000) 288(5472):1765-1769.
   PubMed Web of Science ®Google Scholar
• JI RR, WOOLF CJ: Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol. Dis. (2001) 8(1):1-10.
   PubMed Web of Science ®Google Scholar
• NITU AN, WALLIHAN R, SKLJAREVSKI V, RAMADAN NM: Emerging trends in the pharmacotherapy of chronic pain. Expert Opin. Investig. Drugs (2003) 12(4):545-559.
   PubMed Web of Science ®Google Scholar
• RICE AS, HILL RG: New treatments for neuropathic pain. Ann. Rev. Med. (2006) 57:535-551.
   PubMed Web of Science ®Google Scholar
• KALSO E, EDWARDS JE, MOORE RA, MCQUAY HJ: Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain (2004) 112(3):372-380.
   PubMed Web of Science ®Google Scholar
• COLLINS SD, CHESSELL IP: Emerging therapies for neuropathic pain. Expert Opin. Emerg. Drugs (2005) 10(1):95-108.
   PubMedGoogle Scholar
• WATKINS LR, MAIER SF: Glia: a novel drug discovery target for clinical pain. Nat. Rev. Drug Discov. (2003) 2(12):973-985.
   PubMed Web of Science ®Google Scholar
• DELEO JA, TANGA FY, TAWFIK VL: Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist (2004) 10(1):40-52.
   PubMed Web of Science ®Google Scholar
• MILLER G: Neuroscience. The dark side of glia. Science (2005) 308(5723):778-781.
   PubMed Web of Science ®Google Scholar
• TSUDA M, INOUE K, SALTER MW: Neuropathic pain and spinal microglia: a big problem from molecules in “small” glia. Trends Neurosci. (2005) 28(2):101-107.
   PubMed Web of Science ®Google Scholar
• MCMAHON SB, CAFFERTY WB, MARCHAND F: Immune and glial cell factors as pain mediators and modulators. Exp. Neurol. (2005) 192(2):444-462.
   PubMed Web of Science ®Google Scholar
• MARCHAND F, PERRETTI M, MCMAHON SB: Role of the immune system in chronic pain. Nat. Rev. Neurosci. (2005) 6(7):521-532.
   PubMed Web of Science ®Google Scholar
• WATKINS LR, HUTCHINSON MR, LEDEBOER A et al.: Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. Brain Behav. Immunol, (2007) 21(2):131-146.
   PubMed Web of Science ®Google Scholar
• WIESELER-FRANK J, MAIER SF, WATKINS LR: Glial activation and pathological pain. Neurochem. Int. (2004) 45(2-3):389-395.
   PubMed Web of Science ®Google Scholar
• MOALEM G, TRACEY DJ: Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. (2006) 51(2):240-264.
   PubMed Web of Science ®Google Scholar
• LAUGHLIN TM, BETHEA JR, YEZIERSKI RP, WILCOX GL: Cytokine involvement in dynorphin-induced allodynia. Pain (2000) 84(2-3):159-167.
   PubMed Web of Science ®Google Scholar
• MILLIGAN ED, SLOANE EM, LANGER SJ et al.: Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, IL-10. Mol. Pain (2005) 1(1):9.
   PubMed Web of Science ®Google Scholar
• MILLIGAN ED, LANGER SJ, SLOANE EM et al.: Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, IL-10. Eur. J. Neurosci. (2005) 21(8):2136-2148.
   PubMed Web of Science ®Google Scholar
• MILLIGAN ED, SLOANE EM, LANGER SJ et al.: Repeated intrathecal injections of plasmid DNA encoding IL-10 produce prolonged reversal of neuropathic pain. Pain (2006) 126(1-3):294-308.
   PubMed Web of Science ®Google Scholar
• LEDEBOER A, JEKICH BM, SLOANE EM et al.: Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav. Immun. (2007) 21(5):686-698.
   PubMed Web of Science ®Google Scholar
• KAWASAKI A, HOSHINO K, OSAKI R, MIZUSHIMA Y, YANO S: Effect of ibudilast: a novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma. J. Asthma (1992) 29(4):245-252.
   PubMed Web of Science ®Google Scholar
• ARMSTEAD WM, MIRRO R, LEFFLER CW, BUSIJA DW: The role of prostanoids in the mediation of responses to KC-404, a novel cerebrovasodilator. J. Pharmacol. Exp. Ther. (1988) 244(1):138-143.
   PubMed Web of Science ®Google Scholar
• FUKUYAMA H, KIMURA J, YAMAGUCHI S et al.: Pharmacological effects of ibudilast on cerebral circulation: a PET study. Neurol. Res. (1993) 15(3):169-173.
   PubMed Web of Science ®Google Scholar
• SHINOHARA Y, KUSUNOKI T, NAKASHIMA M: Clinical efficacy of ibudilast on vertigo and dizziness observed in patients with cerebral infarction in the chronic stage – a double-blind, randomized, placebo-controlled trial with a run-in period. Shinnkeitiryougaku (Neurol. Ther.) (2002) 19:177-187.
   Google Scholar
• NOGUCHI K, KOBAYASHI K, NISHIKIBE M, IKEMETO F: Preventive effect of ophthalmic ibudilast on experimental allergic conjunctivitis in the guinea pig. J. Eye (1994) 11:1747-1754.
   Google Scholar
• YOKOGAKI S, SUZUKI Y, OHASHI M: Introduction of a new anti-allergic ophthalmic solution: ibudilast ophtalmic solution (Ketas Eye drops). Japanese J. Ocular Pharmacol. (2002) 16:24-28.
   Google Scholar
• OHASHI M, OHKUBO H, KITO J, NISHINO K: A new vasodilator 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) has a dual mechanism of action on platelet aggregation. Arch. Int. Pharmacodyn. Ther. (1986) 283(2):321-334.
   PubMedGoogle Scholar
• KISHI Y, OHTA S, KASUYA N et al.: Ibudilast modulates platelet-endothelium interaction mainly through cyclic GMP-dependent mechanism. J. Cardiovasc. Pharmacol. (2000) 36(1):65-70.
   PubMed Web of Science ®Google Scholar
• RILE G, YATOMI Y, QI R, SATOH K, OZAKI Y: Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells. Thromb. Res. (2001) 102(3):239-246.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, VILLAMIL ME, SCOTT LC et al.: Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone. Br. J. Pharmacol. (1994) 111(4):1081-1088.
   PubMed Web of Science ®Google Scholar
• BOSWELL-SMITH V, SPINA D, PAGE CP: Phosphodiesterase inhibitors. Br. J. Pharmacol. (2006) 147:S252-S257.
   PubMed Web of Science ®Google Scholar
• MENNITI FS, FARACI WS, SCHMIDT CJ: Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. (2006) 5(8):660-670.
   PubMed Web of Science ®Google Scholar
• SUZUMURA A, ITO A, YOSHIKAWA M, SAWADA M: Ibudilast suppresses TNF-α production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. (1999) 837(1-2):203-212.
   PubMed Web of Science ®Google Scholar
• KISHI Y, OHTA S, KASUYA N et al.: Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall. Cardiovasc. Drug Rev. (2001) 19(3):215-225.
   PubMed Web of Science ®Google Scholar
• HUANG Z, LIU S, ZHANG L et al.: Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sci. (2006) 78(23):2663-2668.
   PubMed Web of Science ®Google Scholar
• GIBSON LC, HASTINGS SF, MCPHEE I et al.: The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family. Eur. J. Pharmacol. (2006) 538(1-3):39-42.
   PubMed Web of Science ®Google Scholar
• KAWANOKUCHI J, MIZUNO T, KATO H, MITSUMA N, SUZUMURA A: Effects of IFN-β on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology (2004) 46(5):734-742.
   PubMed Web of Science ®Google Scholar
• MIZUNO T, KUROTANI T, KOMATSU Y et al.: Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology (2004) 46(3):404-411.
   PubMed Web of Science ®Google Scholar
• LEDEBOER A, LIU T, SHUMILLA JA et al.: The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. (2007) (In Press).
   Google Scholar
• TOMINAGA Y, NAKAMURA Y, TSUJI K, SHIBATA T, KATAOKA K: Ibudilast protects against neuronal damage induced by glutamate in cultured hippocampal neurons. Clin. Exp. Pharmacol. Physiol. (1996) 23(6-7):519-523.
   PubMed Web of Science ®Google Scholar
• TAKUMA K, LEE E, ENOMOTO R et al.: Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. Br. J. Pharmacol. (2001) 133(6):841-848.
   PubMed Web of Science ®Google Scholar
• YOSHIOKA A, SHIMIZU Y, HIROSE G, KITASATO H, PLEASURE D: Cyclic AMP-elevating agents prevent oligodendroglial excitotoxicity. J. Neurochem. (1998) 70(6):2416-2423.
   PubMed Web of Science ®Google Scholar
• YOSHIOKA A, YAMAYA Y, SAIKI S et al.: Cyclic GMP/cyclic GMP-dependent protein kinase system prevents excitotoxicity in an immortalized oligodendroglial cell line. J. Neurochem. (2000) 74(2):633-640.
   PubMed Web of Science ®Google Scholar
• YASAKI S, OHSHIMA J, KUNIKA N, SOMEYA K: Effect of ibudilast on experimental diabetic neuropathy. J. Japan Diab. Soc. (1994) 37(3):215-222.
   Web of Science ®Google Scholar
• FUJIMOTO T, SAKODA S, FUJIMURA H, YANAGIHARA T: Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J. Neuroimmunol. (1999) 95(1-2):35-42.
   PubMed Web of Science ®Google Scholar
• YOSHIOKA M, SUDA N, MORI K et al.: Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia. Pharmacol. Res. (2002) 45(4):305-311.
   PubMed Web of Science ®Google Scholar
• WAKITA H, TOMIMOTO H, AKIGUCHI I et al.: Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res. (2003) 992(1):53-59.
   PubMed Web of Science ®Google Scholar
• KAGITANI-SHIMONO K, MOHRI I, FUJITANI Y et al.: Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J. Neuroinflammation (2005) 2(1):10.
   PubMed Web of Science ®Google Scholar
• BENNETT GJ, XIE YK: A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain (1988) 33(1):87-107.
   PubMed Web of Science ®Google Scholar
• KIM SH, CHUNG JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain (1992) 50(3):355-363.
   PubMed Web of Science ®Google Scholar
• POLOMANO RC, MANNES AJ, CLARK US, BENNETT GJ: A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain (2001) 94(3):293-304.
   PubMed Web of Science ®Google Scholar
• OSSIPOV MH, LAI J, MALAN TP Jr, PORRECA F: Spinal and supraspinal mechanisms of neuropathic pain. Ann. NY Acad. Sci. (2000) 909:12-24.
   PubMed Web of Science ®Google Scholar
• KING T, RAO S, VANDERAH T et al.: Differential blockade of nerve injury-induced shift in weight bearing and thermal and tactile hypersensitivity by milnacipran. J. Pain (2006) 7(7):513-520.
   PubMed Web of Science ®Google Scholar
• BENNETT MI, SIMPSON KH: Gabapentin in the treatment of neuropathic pain. Palliat. Med. (2004) 18(1):5-11.
   PubMed Web of Science ®Google Scholar
• BACKONJA M, BEYDOUN A, EDWARDS KR et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA (1998) 280(21):1831-1836.
   PubMed Web of Science ®Google Scholar
• ROWBOTHAM M, HARDEN N, STACEY B, BERNSTEIN P, MAGNUS-MILLER L: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA (1998) 280(21):1837-1842.
   PubMed Web of Science ®Google Scholar
• VAN DE VUSSE AC, STOMP-VAN DEN BERG SG, KESSELS AH, WEBER WE: Randomised controlled trial of gabapentin in complex regional pain syndrome type 1 [ISRCTN84121379]. BMC Neurol. (2004) 4:13.
   PubMedGoogle Scholar
• HO KY, GAN TJ, HABIB AS: Gabapentin and postoperative pain – a systematic review of randomized controlled trials. Pain (2006) 126(1-3):91-101.
   PubMed Web of Science ®Google Scholar
• CATA JP, WENG HR, LEE BN, REUBEN JM, DOUGHERTY PM: Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. (2006) 72(3):151-169.
   PubMed Web of Science ®Google Scholar
• MCNICOL E, HOROWICZ-MEHLER N, FISK RA et al.: Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J. Pain (2003) 4(5):231-256.
   PubMed Web of Science ®Google Scholar
• GUTSTEIN HB, AKIL H: Opioid analgesics. In: Goodman & Gilman's the Pharmacological Basis of Therapeutics. Hardman JG, Limbird L (Eds), McGraw-Hill, New York, NY, USA (2001) 10:569-619.
   Google Scholar
• BALLANTYNE JC, MAO J: Opioid therapy for chronic pain. N. Engl. J. Med. (2003) 349(20):1943-1953.
   PubMed Web of Science ®Google Scholar
• WATKINS LR, HUTCHINSON MR, JOHNSTON IN, MAIER SF: Glia: novel counter-regulators of opioid analgesia. Trends Neurosci. (2005) 28(12):661-669.
   PubMed Web of Science ®Google Scholar
• SONG P, ZHAO ZQ: The involvement of glial cells in the development of morphine tolerance. Neurosci. Res. (2001) 39(3):281-286.
   PubMed Web of Science ®Google Scholar
• RAGHAVENDRA V, RUTKOWSKI MD, DELEO JA: The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. (2002) 22(22):9980-9989.
   PubMed Web of Science ®Google Scholar
• RAGHAVENDRA V, TANGA FY, DELEO JA: Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology (2004) 29(2):327-334.
   PubMed Web of Science ®Google Scholar
• NARITA M, SUZUKI M, YAJIMA Y et al.: Neuronal protein kinase C γ-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo administration of morphine. Eur. J. Neurosci. (2004) 19(2):479-484.
   PubMed Web of Science ®Google Scholar
• TAWFIK VL, LACROIX-FRALISH ML, NUTILE-MCMENEMY N, DELEO JA: Transcriptional and translational regulation of glial activation by morphine in a rodent model of neuropathic pain. J. Pharmacol. Exp. Ther. (2005) 313(3):1239-1247.
   PubMed Web of Science ®Google Scholar
• RAGHAVENDRA V, TANGA F, RUTKOWSKI MD, DELEO JA: Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines. Pain (2003) 104(3):655-664.
   PubMed Web of Science ®Google Scholar
• JOHNSTON IN, MILLIGAN ED, WIESELER-FRANK J et al.: A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J. Neurosci. (2004) 24(33):7353-7365.
   PubMed Web of Science ®Google Scholar
• SHAVIT Y, WOLF G, GOSHEN I, LIVSHITS D, YIRMIYA R: Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance. Pain (2005) 115(1-2):50-59.
   PubMed Web of Science ®Google Scholar
• NARITA M, SUZUKI M, NIIKURA K et al.: μ-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to μ-opioid receptor agonists: comparison between etorphine and morphine. Neuroscience (2006) 138(2):609-619.
   PubMed Web of Science ®Google Scholar
• OSSIPOV MH, LOPEZ Y, NICHOLS ML, BIAN D, PORRECA F: Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. Neurosci. Lett. (1995) 199(2):83-86.
   PubMed Web of Science ®Google Scholar
• GUL H, YILDIZ O, DOGRUL A, YESILYURT O, ISIMER A: The interaction between IL-1β and morphine: possible mechanism of the deficiency of morphine-induced analgesia in diabetic mice. Pain (2000) 89(1):39-45.
   PubMed Web of Science ®Google Scholar
• NARITA M, MIYOSHI K, SUZUKI T: Functional reduction in μ-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat. Neuroscience (2007) 144(3):777-782.
   PubMed Web of Science ®Google Scholar
• CHOU R, CLARK E, HELFAND M: Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J. Pain Symptom Manage. (2003) 26(5):1026-1048.
   PubMed Web of Science ®Google Scholar
• DICKENSON AH, SUZUKI R: Opioids in neuropathic pain: clues from animal studies. Eur. J. Pain (2005) 9(2):113-116.
   PubMed Web of Science ®Google Scholar
• NARITA M, MIYATAKE M, SHIBASAKI M et al.: Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology (2006) 31(11):2476-2488.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY PM, ARONOWSKI J, SAMORAJSKI T, DAFNY N: Opiate antinociception is altered by immunemodification: the effect of interferon, cyclosporine and radiation-induced immune suppression upon acute and long-term morphine activity. Brain Res. (1986) 385(2):401-404.
   PubMed Web of Science ®Google Scholar
• SAWYNOK J: Adenosine receptor activation and nociception. Eur. J. Pharmacol. (1998) 347(1):1-11.
   PubMed Web of Science ®Google Scholar
• WU WP, HAO JX, FREDHOLM BB, WIESENFELD-HALLIN Z, XU XJ: Effect of acute and chronic administration of caffeine on pain-like behaviors in rats with partial sciatic nerve injury. Neurosci. Lett. (2006) 402(1-2):164-166.
   PubMed Web of Science ®Google Scholar
• BURNOUF C, PRUNIAUX MP: Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr. Pharm. Des. (2002) 8(14):1255-1296.
   PubMed Web of Science ®Google Scholar
• ZHANG KY, IBRAHIM PN, GILLETTE S, BOLLAG G: Phosphodiesterase-4 as a potential drug target. Expert Opin. Ther. Targets (2005) 9(6):1283-1305.
   PubMed Web of Science ®Google Scholar
• GONG B, VITOLO OV, TRINCHESE F et al.: Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. (2004) 114(11):1624-1634.
   PubMed Web of Science ®Google Scholar
• SOMMER N, LOSCHMANN PA, NORTHOFF GH et al.: The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. (1995) 1(3):244-248.
   PubMed Web of Science ®Google Scholar
• NIKULINA E, TIDWELL JL, DAI HN, BREGMAN BS, FILBIN MT: The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc. Natl. Acad. Sci. USA (2004) 101(23):8786-8790.
   PubMed Web of Science ®Google Scholar
• FRANCISCHI JN, YOKORO CM, POOLE S et al.: Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur. J. Pharmacol. (2000) 399(2-3):243-249.
   PubMed Web of Science ®Google Scholar
• KUMAR A, JAIN NK, KULKARNI SK: Analgesic and anti-inflammatory effects of phosphodiesterase inhibitors. Indian J. Exp. Biol. (2000) 38(1):26-30.
   PubMedGoogle Scholar
• YOSHIKAWA M, SUZUMURA A, TAMARU T, TAKAYANAGI T, SAWADA M: Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult. Scler. (1999) 5(2):126-133.
   PubMed Web of Science ®Google Scholar
• ZHANG B, YANG L, KONISHI Y et al.: Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology (2002) 42(2):262-269.
   PubMed Web of Science ®Google Scholar
• RINGHEIM GE: Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia. Ann. NY Acad. Sci. (2000) 903:529-534.
   PubMed Web of Science ®Google Scholar
• SUZUMURA A, NAKAMURO T, TAMARU T, TAKAYANAGI T: Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors. Mult. Scler. (2000) 6(1):56-58.
   PubMed Web of Science ®Google Scholar
• WU YP, MCRAE A, RUDOLPHI K, LING EA: Propentofylline attenuates microglial reaction in the rat spinal cord induced by middle cerebral artery occlusion. Neurosci. Lett. (1999) 260(1):17-20.
   PubMed Web of Science ®Google Scholar
• SWEITZER SM, SCHUBERT P, DELEO JA: Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther. (2001) 297(3):1210-1217.
   PubMed Web of Science ®Google Scholar
• TAWFIK VL, NUTILE-MCMENEMY N, LACROIX-FRALISH ML, DELEO JA: Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav. Immun. (2007) 21(2):238-246.
   PubMed Web of Science ®Google Scholar
• LU CH, CHAO PC, BOREL CO et al.: Preincisional intravenous pentoxifylline attenuating perioperative cytokine response, reducing morphine consumption, and improving recovery of bowel function in patients undergoing colorectal cancer surgery. Anesth. Analg. (2004) 99(5):1465-1471; table of contents.
   PubMed Web of Science ®Google Scholar
• LIU J, FENG X, YU M et al.: Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain. Neurosci. Lett. (2007) 412(3):268-272.
   PubMed Web of Science ®Google Scholar
• MIKA J, OSIKOWICZ M, MAKUCH W, PRZEWLOCKA B: Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. Eur. J. Pharmacol. (2007) 560(2-3):142-149.
   PubMed Web of Science ®Google Scholar
• ITOH A, NODA Y, MAMIYA T, HASEGAWA T, NABESHIMA T: A therapeutic strategy to prevent morphine dependence and tolerance by coadministration of cAMP-related reagents with morphine. Methods Find. Exp. Clin. Pharmacol. (1998) 20(7):619-625.
   PubMed Web of Science ®Google Scholar
• MAMIYA T, NODA Y, REN X et al.: Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor. Br. J. Pharmacol. (2001) 132(5):1111-1117.
   PubMed Web of Science ®Google Scholar
• HAMDY MM, MAMIYA T, NODA Y et al.: A selective phosphodiesterase IV inhibitor, rolipram blocks both withdrawal behavioral manifestations, and c-Fos protein expression in morphine dependent mice. Behav. Brain Res. (2001) 118(1):85-93.
   PubMed Web of Science ®Google Scholar
• THOMPSON BE, SACHS BD, KANTAK KM, CHERRY JA: The type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice. Eur. J. Neurosci. (2004) 19(9):2561-2568.
   PubMed Web of Science ®Google Scholar
• SWEITZER SM, PAHL JL, DELEO JA: Propentofylline attenuates vincristine-induced peripheral neuropathy in the rat. Neurosci. Lett. (2006) 400(3):258-261.
   PubMed Web of Science ®Google Scholar
• IRIKURA T, KUDO Y, OHKUBO H et al.: Effect of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (KC-404) on the cardiovascular system. Oyo Yakuri (1983) 25(2):283.
   Google Scholar
• OHTOMO H: Effect of ibudilast (Ketas) in preventing the recurrence of cerebral infarction. Yakuri to Rinsho (Jpn. Pharmacol. Ther.) (1995) 23(9):139-157.
   Google Scholar
• FENG J, MISU T, FUJIHARA K et al.: Ibudilast, a nonselective phosphodiesterase inhibitor, regulates TH1/TH2 balance and NKT cell subset in multiple sclerosis. Mult. Scler. (2004) 10(5):494-498.
   PubMed Web of Science ®Google Scholar
• BERG-JOHNSEN J, PAULSEN RE, FONNUM F, LANGMOEN IA: Changes in evoked potentials and amino acid content during fluorocitrate action studied in rat hippocampal cortex. Exp. Brain Res. (1993) 96(2):241-246.
   PubMed Web of Science ®Google Scholar
• RAGHAVENDRA V, TANGA F, DELEO JA: Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. (2003) 306(2):624-630.
   PubMed Web of Science ®Google Scholar
• LEDEBOER A, SLOANE EM, MILLIGAN ED et al.: Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain (2005) 115(1-2):71-83.
   PubMed Web of Science ®Google Scholar
• HARTRICK CT: Increased production of nitric oxide stimulated by interferon-γ from peripheral blood monocytes in patients with complex regional pain syndrome. Neurosci. Lett. (2002) 323(1):75-77.
   PubMed Web of Science ®Google Scholar
• KOTANI N, KUDO R, SAKURAI Y et al.: Cerebrospinal fluid IL 8 concentrations and the subsequent development of postherpetic neuralgia. Am. J. Med. (2004) 116(5):318-324.
   PubMed Web of Science ®Google Scholar
• ALEXANDER GM, VAN RIJN MA, VAN HILTEN JJ, PERREAULT MJ, SCHWARTZMAN RJ: Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain (2005) 116(3):213-219.
   PubMed Web of Science ®Google Scholar
• UCEYLER N, VALENZA R, STOCK M et al.: Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum. (2006) 54(8):2656-2664.
   PubMed Web of Science ®Google Scholar
• ALEXANDER GM, PERREAULT MJ, REICHENBERGER ER, SCHWARTZMAN RJ: Changes in immune and glial markers in the CSF of patients with complex regional pain syndrome. Brain Behav. Immun. (2007) 21(5):668-676.
   PubMed Web of Science ®Google Scholar
• KONTINEN VK, MEERT TF: Predictive validity of neuropathic pain models in pharmacological studies with a behavioral outcome in the rat: a systematic review. In: Proceedings of the 10th World Congress on Pain. Dostrovsky JO, Carr DB, Koltzenburg M (Eds), IASP Press, Seattle, WA, USA (2003):489-498.
   Google Scholar
• BEGGS S, SALTER MW: Neuropathic pain: symptoms, models, and mechanisms. Drug Dev. Res. (2006) 67(4):289-301.
   Web of Science ®Google Scholar